Is Now The Time To Invest In AstraZeneca plc, Indivior plc And Skyepharma plc?

Stock market turmoil could have uncovered value in AstraZeneca plc (LON: AZN), Indivior plc (LON: INDV) and Skyepharma plc (LON: SKP)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Has recent stock market volatility exposed any bargains in the pharmaceutical sector? Today, I’m looking at AstraZeneca (LSE: AZN), Indivior (LSE: INDV) and Skyepharma (LSE: SKP).

Slide in earnings slowing

AstraZeneca’s focus on controlling costs is combining with progress developing new drugs to arrest the firm’s slide in profits. City analysts following the firm expect earnings to drop 2% this year and 4% next year. That’s good progress compared to the double-digit falls we’ve seen recently.

Since Pfizer’s takeover approach, there seems to be a premium built in to the share price, perhaps due to hopes of another offer appearing. However, the share price eased back around 13% in the months since the spring. Today’s 4112p has the firm trading on a forward price-to-earnings ratio (PER) of just below 16 for 2016, and the forward dividend yield is 4.4%. Forward earnings will likely cover that payout around 1.5 times.

That’s not an obvious bargain. However, if the development pipeline delivers rising profits going forward, such growth could drive the share price higher. The timescale likely for such an outcome is unclear. Meanwhile, AstraZeneca retains its ‘defensive’ characteristics, which combines with that growth potential. I’m happy to watch from the sidelines.

A focus on addictions

Profits are falling at Indivior due to generic competition. City analysts following the firm expect earnings to plunge 48% this year and 27% next year. The company focuses on producing treatments for addictions, which are still generating enough earnings to cover the dividend payout around twice. At today’s 217p share price, the forward dividend yield runs at 3.3% for 2016 and Indivior is priced at around 15 times forward earnings.

Reckitt Benckiser (LSE: RB) spun out Indivior at the end of 2014, and the shares are up around 60% since the start of this year. Despite slipping earnings, the firm’s chief executive reckons Indivior’s development pipeline will deliver good growth in the future. Indivior’s current revenues depend on one major product line, a treatment for opioid dependence branded Suboxone and Subutex in its various forms. It’s essential that the up-and-coming pipeline captures the market; otherwise, things could turn sour for the company and its investors.

Indivior is worth watching but carries too much uncertainty to interest me just now.

Growth on track

Skyepharma’s focus on developing oral and inhalation pharmaceutical products produced some stunning growth numbers in recent years. After rising 944% last year, City analysts following the firm expect earnings to ease off by 19% this year followed by another 43% up-spurt next year.

At a share price of 338p, the forward PER sits at almost 16 for 2016 and the firm doesn’t pay a dividend. The shares rose more than 600% since the end of 2013 and Skypharma remains in full-on growth mode, although shareholder gains will likely be slower going forward.

Skypharma strikes me as well worth watching with the aim of investing if further general market weakness knocks the shares back a bit.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »